Andrew Dehennis1, Mark A Mortellaro2, Sorin Ioacara3. 1. Senseonics, Inc, Germantown, MD, USA andy.dehennis@senseonics.com. 2. Senseonics, Inc, Germantown, MD, USA. 3. Carol Davila University, Faculty of General Medicine and Elias Emergency University Hospital, Bucharest, Romania.
Abstract
BACKGROUND: Continuous glucose monitoring (CGM), which enables real-time glucose display and trend information as well as real-time alarms, can improve glycemic control and quality of life in patients with diabetes mellitus. Previous reports have described strategies to extend the useable lifetime of a single sensor from 1-2 weeks to 28 days. The present multisite study describes the characterization of a sensing platform achieving 90 days of continuous use for a single, fully implanted sensor. METHOD: The Senseonics CGM system is composed of a long-term implantable glucose sensor and a wearable smart transmitter. Study subjects underwent subcutaneous implantation of sensors in the upper arm. Eight-hour clinic sessions were performed every 14 days, during which sensor glucose values were compared against venous blood lab reference measurements collected every 15 minutes using mean absolute relative differences (MARDs). RESULTS: All subjects (mean ± standard deviation age: 43.5 ± 11.0 years; with 10 sensors inserted in men and 14 in women) had type 1 diabetes mellitus. Most (22 of 24) sensors reported glucose values for the entire 90 days. The MARD value was 11.4 ± 2.7% (range, 8.1-19.5%) for reference glucose values between 40-400 mg/dl. There was no significant difference in MARD throughout the 90-day study (P = .31). No serious adverse events were noted. CONCLUSIONS: The Senseonics CGM, composed of an implantable sensor, external smart transmitter, and smartphone app, is the first system that uses a single sensor for continuous display of accurate glucose values for 3 months.
BACKGROUND: Continuous glucose monitoring (CGM), which enables real-time glucose display and trend information as well as real-time alarms, can improve glycemic control and quality of life in patients with diabetes mellitus. Previous reports have described strategies to extend the useable lifetime of a single sensor from 1-2 weeks to 28 days. The present multisite study describes the characterization of a sensing platform achieving 90 days of continuous use for a single, fully implanted sensor. METHOD: The Senseonics CGM system is composed of a long-term implantable glucose sensor and a wearable smart transmitter. Study subjects underwent subcutaneous implantation of sensors in the upper arm. Eight-hour clinic sessions were performed every 14 days, during which sensor glucose values were compared against venous blood lab reference measurements collected every 15 minutes using mean absolute relative differences (MARDs). RESULTS: All subjects (mean ± standard deviation age: 43.5 ± 11.0 years; with 10 sensors inserted in men and 14 in women) had type 1 diabetes mellitus. Most (22 of 24) sensors reported glucose values for the entire 90 days. The MARD value was 11.4 ± 2.7% (range, 8.1-19.5%) for reference glucose values between 40-400 mg/dl. There was no significant difference in MARD throughout the 90-day study (P = .31). No serious adverse events were noted. CONCLUSIONS: The Senseonics CGM, composed of an implantable sensor, external smart transmitter, and smartphone app, is the first system that uses a single sensor for continuous display of accurate glucose values for 3 months.
Authors: Daniela Bruttomesso; Anne Farret; Silvana Costa; Maria Cristina Marescotti; Monica Vettore; Angelo Avogaro; Antonio Tiengo; Chiara Dalla Man; Jerome Place; Andrea Facchinetti; Stefania Guerra; Lalo Magni; Giuseppe De Nicolao; Claudio Cobelli; Eric Renard; Alberto Maran Journal: J Diabetes Sci Technol Date: 2009-09-01
Authors: Andrew Farmer; Alisha Wade; Elizabeth Goyder; Patricia Yudkin; David French; Anthea Craven; Rury Holman; Ann-Louise Kinmonth; Andrew Neil Journal: BMJ Date: 2007-06-25
Authors: Lauren M Huyett; Rowena Mittal; Howard C Zisser; Evan S Luxon; Alex Yee; Eyal Dassau; Francis J Doyle; Daniel R Burnett Journal: J Diabetes Sci Technol Date: 2016-08-22
Authors: Elisabetta Primiceri; Maria Serena Chiriacò; Francesca M Notarangelo; Antonio Crocamo; Diego Ardissino; Marco Cereda; Alessandro P Bramanti; Marco A Bianchessi; Gianluigi Giannelli; Giuseppe Maruccio Journal: Sensors (Basel) Date: 2018-10-24 Impact factor: 3.576